Related Experiment Video
Updated: Dec 21, 2025

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
Published on: April 17, 2017
[Lipid metabolism alterations produced by hepatitis C virus in patients with chronic infection.]
Ainara Muñoz-Cabrejas1, Silvia Espina Cadena2, José Miguel Arbonés-Mainar3
1Adipocyte and Fat Biology Laboratory (AdipoFat). Unidad de Investigación Traslacional. Hospital Universitario Miguel Servet. Instituto Aragonés de Ciencias de la Salud (IACS). Instituto de Investigación Sanitaria de Aragón (IIS Aragón). Zaragoza. España.
Insights
Chronic hepatitis C virus (HCV) infection lowers lipid levels but paradoxically increases cardiovascular disease risk. Further research is needed on direct-acting antivirals and their impact on lipid metabolism and heart health.
Area of Science:
- Hepatology
- Cardiology
- Lipid Metabolism
Background:
- Chronic hepatitis C virus (HCV) infection is associated with an altered lipid profile.
- Despite a seemingly favorable lipid profile, HCV patients exhibit increased cardiovascular events.
- The relationship between HCV-induced metabolic changes and cardiovascular disease risk requires clarification.
Purpose of the Study:
- To review and synthesize studies on HCV's impact on lipid metabolism.
- To investigate the association between HCV infection, lipid changes, and cardiovascular disease.
Main Methods:
- Bibliographic search of Medline and Scopus databases (January 2008 - February 2019).
- Inclusion and exclusion criteria applied to 901 identified publications.
- Review of 10 selected studies.
Main Results:
- Chronic HCV infection decreased total cholesterol and lipid fractions.
- No significant association found with triglyceride levels.
- Evidence suggests HCV infection increases atherosclerosis and cardiovascular disease risk.
Conclusions:
- Chronic HCV infection exerts a lipid-lowering effect and elevates cardiovascular risk.
- Prospective studies are necessary to evaluate direct-acting antivirals' effects on lipid metabolism and cardiovascular risk.
Background:
Chronic infection with the hepatitis C virus (HCV) is known to generate an apparently favorable lipid profile. Paradoxically, these patients present an increase in concomitant cardiovascular events. The objectives of the present review were to analyze and synthesize studies that inquired into the changes produced by hepatitis C virus (HCV) in the lipid metabolism of patients with chronic infection, and about whether these modifications can be associated with subsequent episodes of cardiovascular diseases.
Methods:
A bibliographic search was carried out in the Medline and Scopus databases of the articles published from January 2008 to February 2019. A total of 901 publications were identified, of which 10 studies that fulfilled the inclusion and exclusion criteria were reviewed.
Results:
It was found that the levels of total cholesterol and its lipid fractions were decreased in patients with chronic HCV infection. There was no clear association with triglyceride levels. In addition, there seemed to be an association between chronic HCV infection and an increased risk of developing atherosclerosis and cardiovascular diseases.
Conclusions:
Chronic HCV infection has a lipid-lowering effect and increases cardiovascular risk. Prospective studies are needed to analyze the effect of new therapies with direct-acting antivirals on lipid metabolism and cardiovascular risk.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

